Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease

Bibliography

• Ott A, Breteler MM, van HF, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995;310(6985):970-3
   PubMedGoogle Scholar
• Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76(5):465-79
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112-17
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995;16(3):271-8
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939-44
   PubMed Web of Science ®Google Scholar
• Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2(6150):1457-9
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217(4558):408-14
   PubMed Web of Science ®Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2(8000):1403
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215(4537):1237-9
   PubMed Web of Science ®Google Scholar
• Hanyu H, Asano T, Sakurai H, et al. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol 2002;23(1):27-32
   PubMed Web of Science ®Google Scholar
• Teipel SJ, Flatz WH, Heinsen H, et al. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 2005;128(Pt 11):2626-44
   PubMedGoogle Scholar
• Muth K, Schonmeyer R, Matura S, et al. Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol Psychiatry 2010;67(6):588-91
   PubMed Web of Science ®Google Scholar
• Francis PT, Palmer AM, Sims NR, et al. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N Engl J Med 1985;313(1):7-11
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013;369(4):341-50
   PubMed Web of Science ®Google Scholar
• Jones RW. Dimebon disappointment. Alzheimers Res Ther 2010;2(5):25
   PubMedGoogle Scholar
• Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 2013;9(4):438-44
   PubMed Web of Science ®Google Scholar
• Pfizer. Aricept product monograph. Pfizer Canada Inc, Kirkland, Quebec; 2013
   Google Scholar
• Eisai, Inc. Aricept [US prescribing information]. Eisai, Inc, Woodcliff Lake, New Jersey, USA; 2013
   Google Scholar
• Galli A, Mori F, Benini L, Cacciarelli N. Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020. Eur J Pharmacol 1994;270(2-3):189-93
   PubMed Web of Science ®Google Scholar
• Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995;18(8):1145-7
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Meurling L, Pettersson T, et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm 2006;113(11):1791-801
   PubMed Web of Science ®Google Scholar
• Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998;46(Suppl 1):1-6
   PubMed Web of Science ®Google Scholar
• Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996;7(6):293-303
   PubMedGoogle Scholar
• Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998;46(Suppl 1):13-18
   PubMedGoogle Scholar
• Kawashima K, Sato A, Yoshizawa M, et al. Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 1994;350(5):523-8
   PubMed Web of Science ®Google Scholar
• Giacobini E, Zhu XD, Williams E, Sherman KA. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996;35(2):205-11
   PubMed Web of Science ®Google Scholar
• Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998;60(2):377-86
   PubMed Web of Science ®Google Scholar
• Kirkby DL, Jones DN, Barnes JC, Higgins GA. Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol 1996;7(6):513-25
   PubMed Web of Science ®Google Scholar
• Smith RD, Kistler MK, Cohen-Williams M, Coffin VL. Cholinergic improvement of a naturally-occurring memory deficit in the young rat. Brain Res 1996;707(1):13-21
   PubMed Web of Science ®Google Scholar
• Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 1998;349(2-3):137-42
   PubMed Web of Science ®Google Scholar
• Kaasinen V, Nagren K, Jarvenpaa T, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002;22(6):615-20
   PubMed Web of Science ®Google Scholar
• Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000;48(3):391-5
   PubMed Web of Science ®Google Scholar
• Ota T, Shinotoh H, Fukushi K, et al. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. Clin Neuropharmacol 2010;33(2):74-8
   PubMed Web of Science ®Google Scholar
• Irie T, Fukushi K, Namba H, et al. Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. J Nucl Med 1996;37(4):649-55
   PubMed Web of Science ®Google Scholar
• Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6(1):4-14
   PubMed Web of Science ®Google Scholar
• Bidzan L, Bidzan M. Withdrawal syndrome after donepezil cessation in a patient with dementia. Neurol Sci 2012;33(6):1459-61
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Hosseini SM, Nordberg A. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors. J Alzheimers Dis 2014;39(2):423-40
   PubMed Web of Science ®Google Scholar
• Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA 1996;93(24):13541-6
   PubMed Web of Science ®Google Scholar
• Shen H, Kihara T, Hongo H, et al. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br J Pharmacol 2010;161(1):127-39
   PubMed Web of Science ®Google Scholar
• Kato K, Hayako H, Ishihara Y, et al. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 1999;260(1):5-8
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Sakata M, Ishii K, et al. High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 2009;12(8):1127-31
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su T. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol 2005;3(4):267-80
   PubMedGoogle Scholar
• Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007;131(3):596-610
   PubMed Web of Science ®Google Scholar
• Tchedre KT, Yorio T. Sigma-1 receptors protect RGC-5 cells from apoptosis by regulating intracellular calcium, Bax levels, and caspase-3 activation. Invest Ophthalmol Vis Sci 2008;49(6):2577-88
   PubMed Web of Science ®Google Scholar
• Yang S, Bhardwaj A, Cheng J, et al. Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2. Anesth Analg 2007;104(5):1179-84. tables
   PubMed Web of Science ®Google Scholar
• van Waarde A, Ramakrishnan NK, Rybczynska AA, et al. The cholinergic system, sigma-1 receptors and cognition. Behav Brain Res 2011;221(2):543-54
   PubMed Web of Science ®Google Scholar
• Mishina M, Ohyama M, Ishii K, et al. Low density of sigma1 receptors in early Alzheimer's disease. Ann Nucl Med 2008;22(3):151-6
   PubMed Web of Science ®Google Scholar
• Ishii K, Kimura Y, Kawamura K, et al. Mapping of sigma1 receptors by 11C-SA4503-distribution and aging effect in normal human brain. Neuroimage 2002;16(S3):S3
   Google Scholar
• Junien JL, Roman FJ, Brunelle G, Pascaud X. JO1784, a novel sigma ligand, potentiates [3H]acetylcholine release from rat hippocampal slices. Eur J Pharmacol 1991;200(2-3):343-5
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Matsuno K, Nakata K, Mita S. Enhancement of acetylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain. J Pharmacol Exp Ther 1996;279(1):106-13
   PubMed Web of Science ®Google Scholar
• Booth RG, Baldessarini RJ. (+)-6,7-benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum tissue. Brain Res 1991;557(1-2):349-52
   PubMed Web of Science ®Google Scholar
• Reeves S, Brown R, Matthews D, et al. No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010;81(1):119-21
   PubMed Web of Science ®Google Scholar
• Shen YC, Wang YH, Chou YC, et al. Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. J Neurochem 2008;104(2):558-72
   PubMed Web of Science ®Google Scholar
• Dun Y, Thangaraju M, Prasad P, et al. Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand. Invest Ophthalmol Vis Sci 2007;48(10):4785-94
   PubMed Web of Science ®Google Scholar
• DeCoster MA, Klette KL, Knight ES, Tortella FC. Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 1995;671(1):45-53
   PubMed Web of Science ®Google Scholar
• Moriguchi S, Zhao X, Marszalec W, et al. Modulation of N-methyl-D-aspartate receptors by donepezil in rat cortical neurons. J Pharmacol Exp Ther 2005;315(1):125-35
   PubMed Web of Science ®Google Scholar
• Maurice T, Meunier J, Feng B, et al. Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 2006;317(2):606-14
   PubMed Web of Science ®Google Scholar
• Martina M, Turcotte ME, Halman S, Bergeron R. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol 2007;578(Pt 1):143-57
   PubMed Web of Science ®Google Scholar
• Hayashi T, Kagaya A, Takebayashi M, et al. Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons. J Pharmacol Exp Ther 1995;275(1):207-14
   PubMed Web of Science ®Google Scholar
• Yoshiyama Y, Kojima A, Ishikawa C, Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimers Dis 2010;22(1):295-306
   PubMed Web of Science ®Google Scholar
• Hall AA, Herrera Y, Ajmo CT Jr, et al. Sigma receptors suppress multiple aspects of microglial activation. Glia 2009;57(7):744-54
   PubMed Web of Science ®Google Scholar
• Antonini V, Prezzavento O, Coradazzi M, et al. Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. J Neurochem 2009;109(3):744-54
   PubMed Web of Science ®Google Scholar
• Chen L, Dai XN, Sokabe M. Chronic administration of dehydroepiandrosterone sulfate (DHEAS) primes for facilitated induction of long-term potentiation via sigma 1 (sigma1) receptor: optical imaging study in rat hippocampal slices. Neuropharmacology 2006;50(3):380-92
   PubMed Web of Science ®Google Scholar
• Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006;149(8):998-1012
   PubMed Web of Science ®Google Scholar
• Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(7):1656-9
   PubMed Web of Science ®Google Scholar
• Leyhe T, Stransky E, Eschweiler GW, et al. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2008;258(2):124-8
   PubMed Web of Science ®Google Scholar
• Hwang J, Hwang H, Lee HW, Suk K. Microglia signaling as a target of donepezil. Neuropharmacology 2010;58(7):1122-9
   PubMed Web of Science ®Google Scholar
• Gambi F, Reale M, Iarlori C, et al. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol 2004;24(3):314-21
   PubMed Web of Science ®Google Scholar
• Reale M, Iarlori C, Gambi F, et al. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 2005;40(3):165-71
   PubMed Web of Science ®Google Scholar
• Richardson C, Gard PR, Klugman A, et al. Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 2013; doi:10.1002/gps.3966; [Epub ahead of print]
   Web of Science ®Google Scholar
• Prvulovic D, Bokde AL, Faltraco F, Hampel H. Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. Prog Neurobiol 2011;95(4):557-69
   PubMed Web of Science ®Google Scholar
• Hampel H, Prvulovic D, Teipel SJ, Bokde AL. Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease. Prog Neurobiol 2011;95(4):570-8
   PubMed Web of Science ®Google Scholar
• Li W, Antuono PG, Xie C, et al. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. Neuroimage 2012;60(2):1083-91
   PubMed Web of Science ®Google Scholar
• Zaidel L, Allen G, Cullum CM, et al. Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report. J Alzheimers Dis 2012;31(Suppl 3):S221-6
   PubMedGoogle Scholar
• Sóle-Padullés C, Bartrés-Faz D, Lladó A, et al. Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease. J Clin Psychopharmacol 2013;33(2):199-205
   PubMed Web of Science ®Google Scholar
• Petrella JR, Prince SE, Krishnan S, et al. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. AJNR Am J Neuroradiol 2009;30(2):411-16
   PubMed Web of Science ®Google Scholar
• Teipel SJ, Drzezga A, Bartenstein P, et al. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl) 2006;187(1):86-94
   PubMed Web of Science ®Google Scholar
• Tune L, Tiseo PJ, Ieni J, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003;11(2):169-77
   PubMed Web of Science ®Google Scholar
• Wang L, Harms MP, Staggs JM, et al. Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. Arch Neurol 2010;67(1):99-106
   PubMed Web of Science ®Google Scholar
• Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003;160(11):2003-11
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005;162(4):676-82
   PubMed Web of Science ®Google Scholar
• Schuff N, Suhy J, Goldman R, et al. An MRI substudy of a donepezil clinical trial in mild cognitive impairment. Neurobiol Aging 2011;32(12):e31-41
   PubMedGoogle Scholar
• Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000;11(6):299-313
   PubMed Web of Science ®Google Scholar
• Shigeta M, Homma A. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 2001;7(4):353-68
   PubMedGoogle Scholar
• Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32(7):1234-51
   PubMed Web of Science ®Google Scholar
• Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006(1):CD001190
   Google Scholar
• Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate Alzheimer's disease.. Neurology 2001;57(3):489-95
   PubMed Web of Science ®Google Scholar
• Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006;21(5-6):353-63
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58(3):427-33
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10(3):195-203
   PubMed Web of Science ®Google Scholar
• Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004;63(4):651-7
   PubMed Web of Science ®Google Scholar
• Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009;72(18):1555-61
   PubMed Web of Science ®Google Scholar
• Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352(23):2379-88
   PubMed Web of Science ®Google Scholar
• Reynolds CFI, Butters MA, Lopez O, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011;68(1):51-60
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 2008;29(9):1285-95
   PubMed Web of Science ®Google Scholar
• Román GC, Wilkinson DG, Doody RS, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005;20(6):338-44
   PubMed Web of Science ®Google Scholar
• Wilkinson D, Roman G, Salloway S, et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. Int J Geriatr Psychiatry 2010;25(3):305-13
   PubMed Web of Science ®Google Scholar
• Román GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010;41(6):1213-21
   PubMed Web of Science ®Google Scholar
• Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72(1):41-52
   PubMed Web of Science ®Google Scholar
• Ikeda M, Mori E, Kosaka K, et al. Long-term safety and efficacy of donepezil in patients with dementia with lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord 2013;36(3-4):229-41
   PubMed Web of Science ®Google Scholar
• Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry 2007;22(9):890-5
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012;3:CD006504
   PubMed Web of Science ®Google Scholar
• Keefe RS, Malhotra AK, Meltzer HY, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008;33(6):1217-28
   PubMed Web of Science ®Google Scholar
• Kohler CG, Martin EA, Kujawski E, et al. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 2007;12(5):412-21
   PubMedGoogle Scholar
• Akhondzadeh S, Gerami M, Noroozian M, et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8):1810-15
   PubMed Web of Science ®Google Scholar
• Fagerlund B, Soholm B, Fink-Jensen A, et al. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol 2007;30(1):3-12
   PubMed Web of Science ®Google Scholar
• Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010;61(6):473-81
   PubMed Web of Science ®Google Scholar
• Balsters JH, O'Connell RG, Martin MP, et al. Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers. PLoS ONE 2011;6(9):e24126
   PubMedGoogle Scholar
• Mumenthaler MS, Yesavage JA, Taylor JL, et al. Psychoactive drugs and pilot performance: a comparison of nicotine, donepezil, and alcohol effects. Neuropsychopharmacology 2003;28(7):1366-73
   PubMed Web of Science ®Google Scholar
• Yousef M, Sheremata S, Kaneta R, et al. Cholinergic enhancement improves visual short-term memory performance. J Vision 2013;13:9
   Google Scholar
• Moraes WS, Poyares DR, Guilleminault C, et al. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep 2006;29(2):199-205
   PubMed Web of Science ®Google Scholar
• Song HR, Woo YS, Wang HR, et al. Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep. Int Clin Psychopharmacol 2013;28(6):346-8
   PubMed Web of Science ®Google Scholar
• Nordström P, Religa D, Wimo A, et al. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J 2013;34(33):2585-91
   PubMed Web of Science ®Google Scholar
• Borroni B, Agosti C, Martini G, et al. Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients. J Neurol Sci 2005;229-230:211-13
   PubMed Web of Science ®Google Scholar
• Mihara M, Ohnishi A, Tomono Y, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993;31(5):223-9
   PubMedGoogle Scholar
• Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993;33(11):1086-91
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998;46(Suppl 1):19-24
   PubMed Web of Science ®Google Scholar
• Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol 2005;1(3):527-36
   PubMedGoogle Scholar
• Rogers SL, Cooper NM, Sukovaty R, et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998;46(Suppl 1):7-12
   PubMedGoogle Scholar
• Cummings JL, Geldmacher D, Farlow M, et al. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neurosci Ther 2013;19(5):294-301
   PubMed Web of Science ®Google Scholar
• Matsui K, Taniguchi S, Yoshimura T. Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. Xenobiotica 1999;29(11):1059-72
   PubMed Web of Science ®Google Scholar
• Kim KA, Lim JL, Kim C, Park JY. Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. Clin Ther 2011;33(7):965-72
   PubMed Web of Science ®Google Scholar
• Reyes JF, Vargas R, Kumar D, et al. Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br J Clin Pharmacol 2004;58(Suppl 1):9-17
   PubMedGoogle Scholar
• Tiseo PJ, Vargas R, Perdomo CA, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol 1998;46(Suppl 1):51-5
   PubMedGoogle Scholar
• Nagy CF, Kumar D, Cullen EI, et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol 2004;58(Suppl 1):18-24
   PubMed Web of Science ®Google Scholar
• Zhao Q, Xie C, Pesco-Koplowitz L, et al. Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol 2003;43(2):180-6
   PubMed Web of Science ®Google Scholar
• Reyes JF, Preskorn SH, Khan A, et al. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol 2004;58(Suppl 1):50-7
   PubMed Web of Science ®Google Scholar
• Nagy CF, Kumar D, Perdomo CA, et al. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol 2004;58(Suppl 1):25-33
   PubMed Web of Science ®Google Scholar
• Okereke CS, Kirby L, Kumar D, et al. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol 2004;58(Suppl 1):41-9
   PubMedGoogle Scholar
• Periclou AP, Ventura D, Sherman T, et al. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004;38(9):1389-94
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998;46(Suppl 1):45-50
   PubMedGoogle Scholar
• Ravic M, Warrington S, Boyce M, et al. Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers. Br J Clin Pharmacol 2004;58(Suppl 1):34-40
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998;46(Suppl 1):40-4
   PubMedGoogle Scholar
• Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998;46(Suppl 1):35-9
   PubMedGoogle Scholar
• Hutson JR, Fischer HD, Wang X, et al. Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study. Drugs Aging 2012;29(3):205-11
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(Suppl 1):25-9
   PubMedGoogle Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(Suppl 1):30-4
   PubMed Web of Science ®Google Scholar
• Marshall K, Fritz K, Thom W, Xiong GL. Toxic interaction between fluoxetine and donepezil: a case of cholinergic toxidrome. J Neuropsychiatry Clin Neurosci 2012;24(2):E50
   PubMed Web of Science ®Google Scholar
• Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53(4):401-9
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50(1):136-45
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158(9):1021-31
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10(3):237-44
   PubMed Web of Science ®Google Scholar